Credit Suisse’s Quince Therapeutics QNCX Stock Holding History

Credit Suisse’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Hold	0	–	–	–	4235
2022 Q2	–	Sell	-55	Closed	-$38.9K	–	4232
2022 Q1	$68K	Buy	55 +5	+10%	+$6.8K	﹤0.01%	3500
2021 Q4	$127K	Sell	50 -2	-4%	-$12.2K	﹤0.01%	4357
2021 Q3	$946K	Buy	52 +4	+8%	+$63.6K	﹤0.01%	3393
2021 Q2	$509K	Sell	48 -9	-16%	-$75.5K	﹤0.01%	3823
2021 Q1	$409K	Sell	57 -87	-60%	-$626K	﹤0.01%	3883
2020 Q4	$799K	Buy	144 +104	+260%	+$921K	﹤0.01%	3495
2020 Q3	$399K	Sell	40 -7	-15%	-$63.7K	﹤0.01%	3506
2020 Q2	$435K	Buy	+47	New	+$431K	﹤0.01%	3399
2019 Q3	–	Sell	-34	Closed	-$289K	–	4229
2019 Q2	$289K	Buy	+34	New	+$203K	﹤0.01%	3697

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Credit Suisse's QNCX Position: Q3 2022 in Review

Credit Suisse held its Quince Therapeutics (QNCX) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4235.

Credit Suisse first reported a position in QNCX in Q2 2019 and has held it in 9 quarters since. The position peaked at $946K in Q3 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

Credit Suisse held 0 shares of Quince Therapeutics worth $0 as of Q3 2022.
Credit Suisse left its Quince Therapeutics share count unchanged in Q3 2022.
Quince Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4235 holding.
Credit Suisse first reported a position in Quince Therapeutics in Q2 2019 and has held it in 9 quarters since.
Credit Suisse's Quince Therapeutics position peaked at $946K in Q3 2021.
58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.